Sequencing in metastatic castrate-resistant prostate cancer with enzalutamide in a post-chemotherapy setting.

e16524Background: Enzalutamide (ENZA) is an oral androgen receptor inhibitor that targets multiple steps within the androgen signaling pathway. It was first approved in August 2012 for the treatmen...